Cargando…

An increase in long non-coding RNA PANDAR is associated with poor prognosis in clear cell renal cell carcinoma

BACKGROUND: Nearly 30% of clear cell renal cell carcinoma (ccRCC) patients present with metastasis at the time of diagnosis, and the prognosis for these patients is poor. Therefore, novel potential prognostic biomarkers and therapeutic targets for ccRCC could be helpful. Emerging evidence indicates...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Yi, Tong, Yanyue, Zhu, Jianyong, Lei, Zhangming, Wan, Lijun, Zhu, Xiuwen, Ye, Feng, Xie, Liping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5445460/
https://www.ncbi.nlm.nih.gov/pubmed/28545465
http://dx.doi.org/10.1186/s12885-017-3339-9
_version_ 1783238896070426624
author Xu, Yi
Tong, Yanyue
Zhu, Jianyong
Lei, Zhangming
Wan, Lijun
Zhu, Xiuwen
Ye, Feng
Xie, Liping
author_facet Xu, Yi
Tong, Yanyue
Zhu, Jianyong
Lei, Zhangming
Wan, Lijun
Zhu, Xiuwen
Ye, Feng
Xie, Liping
author_sort Xu, Yi
collection PubMed
description BACKGROUND: Nearly 30% of clear cell renal cell carcinoma (ccRCC) patients present with metastasis at the time of diagnosis, and the prognosis for these patients is poor. Therefore, novel potential prognostic biomarkers and therapeutic targets for ccRCC could be helpful. Emerging evidence indicates that lncRNAs play important roles in cancer tumorigenesis and could be used as potential biomarkers or therapeutic targets. PANDAR (promoter of CDKN1A antisense DNA damage activated RNA) is a relatively novel lncRNA that plays an important role in the development of multiple cancers. However, the clinical significance and molecular mechanism of PANDAR in ccRCC are still elusive. In the present study, we attempted to elucidate the role of PANDAR in ccRCC. METHODS: The relative expression level of lncRNA PANDAR was quantified by real-time qPCR in 62 paired ccRCC tissues and in renal cancer cell lines, and its association with overall survival was assessed by statistical analysis. The biological functions of lncRNA PANDAR on ccRCC cells were determined both in vitro and in vivo. RESULTS: PANDAR expression was significantly upregulated in tumor tissues and cell lines compared with normal counterparts. Moreover, PANDAR served as an independent predictor of overall survival, and increased PANDAR expression was positively correlated with an advanced TNM stage. Further experiments demonstrated that PANDAR silencing can significantly inhibit cell proliferation and invasion, induce cell cycle arrest in the G1 phase and significantly promote apoptosis in 7860 and Caki-1 cell lines. In addition, in vivo experiments confirmed that downregulation of PANDAR inhibited the tumorigenic ability of 7860 cells in nude mice. Silencing of PANDAR also inhibited the expression of Bcl-2 and Mcl-1 and upregulated the expression of Bax in vivo. CONCLUSIONS: Our results suggest that PANDAR is involved in ccRCC progression and may serve as a potential prognostic biomarker and therapeutic target.
format Online
Article
Text
id pubmed-5445460
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-54454602017-05-30 An increase in long non-coding RNA PANDAR is associated with poor prognosis in clear cell renal cell carcinoma Xu, Yi Tong, Yanyue Zhu, Jianyong Lei, Zhangming Wan, Lijun Zhu, Xiuwen Ye, Feng Xie, Liping BMC Cancer Research Article BACKGROUND: Nearly 30% of clear cell renal cell carcinoma (ccRCC) patients present with metastasis at the time of diagnosis, and the prognosis for these patients is poor. Therefore, novel potential prognostic biomarkers and therapeutic targets for ccRCC could be helpful. Emerging evidence indicates that lncRNAs play important roles in cancer tumorigenesis and could be used as potential biomarkers or therapeutic targets. PANDAR (promoter of CDKN1A antisense DNA damage activated RNA) is a relatively novel lncRNA that plays an important role in the development of multiple cancers. However, the clinical significance and molecular mechanism of PANDAR in ccRCC are still elusive. In the present study, we attempted to elucidate the role of PANDAR in ccRCC. METHODS: The relative expression level of lncRNA PANDAR was quantified by real-time qPCR in 62 paired ccRCC tissues and in renal cancer cell lines, and its association with overall survival was assessed by statistical analysis. The biological functions of lncRNA PANDAR on ccRCC cells were determined both in vitro and in vivo. RESULTS: PANDAR expression was significantly upregulated in tumor tissues and cell lines compared with normal counterparts. Moreover, PANDAR served as an independent predictor of overall survival, and increased PANDAR expression was positively correlated with an advanced TNM stage. Further experiments demonstrated that PANDAR silencing can significantly inhibit cell proliferation and invasion, induce cell cycle arrest in the G1 phase and significantly promote apoptosis in 7860 and Caki-1 cell lines. In addition, in vivo experiments confirmed that downregulation of PANDAR inhibited the tumorigenic ability of 7860 cells in nude mice. Silencing of PANDAR also inhibited the expression of Bcl-2 and Mcl-1 and upregulated the expression of Bax in vivo. CONCLUSIONS: Our results suggest that PANDAR is involved in ccRCC progression and may serve as a potential prognostic biomarker and therapeutic target. BioMed Central 2017-05-25 /pmc/articles/PMC5445460/ /pubmed/28545465 http://dx.doi.org/10.1186/s12885-017-3339-9 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Xu, Yi
Tong, Yanyue
Zhu, Jianyong
Lei, Zhangming
Wan, Lijun
Zhu, Xiuwen
Ye, Feng
Xie, Liping
An increase in long non-coding RNA PANDAR is associated with poor prognosis in clear cell renal cell carcinoma
title An increase in long non-coding RNA PANDAR is associated with poor prognosis in clear cell renal cell carcinoma
title_full An increase in long non-coding RNA PANDAR is associated with poor prognosis in clear cell renal cell carcinoma
title_fullStr An increase in long non-coding RNA PANDAR is associated with poor prognosis in clear cell renal cell carcinoma
title_full_unstemmed An increase in long non-coding RNA PANDAR is associated with poor prognosis in clear cell renal cell carcinoma
title_short An increase in long non-coding RNA PANDAR is associated with poor prognosis in clear cell renal cell carcinoma
title_sort increase in long non-coding rna pandar is associated with poor prognosis in clear cell renal cell carcinoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5445460/
https://www.ncbi.nlm.nih.gov/pubmed/28545465
http://dx.doi.org/10.1186/s12885-017-3339-9
work_keys_str_mv AT xuyi anincreaseinlongnoncodingrnapandarisassociatedwithpoorprognosisinclearcellrenalcellcarcinoma
AT tongyanyue anincreaseinlongnoncodingrnapandarisassociatedwithpoorprognosisinclearcellrenalcellcarcinoma
AT zhujianyong anincreaseinlongnoncodingrnapandarisassociatedwithpoorprognosisinclearcellrenalcellcarcinoma
AT leizhangming anincreaseinlongnoncodingrnapandarisassociatedwithpoorprognosisinclearcellrenalcellcarcinoma
AT wanlijun anincreaseinlongnoncodingrnapandarisassociatedwithpoorprognosisinclearcellrenalcellcarcinoma
AT zhuxiuwen anincreaseinlongnoncodingrnapandarisassociatedwithpoorprognosisinclearcellrenalcellcarcinoma
AT yefeng anincreaseinlongnoncodingrnapandarisassociatedwithpoorprognosisinclearcellrenalcellcarcinoma
AT xieliping anincreaseinlongnoncodingrnapandarisassociatedwithpoorprognosisinclearcellrenalcellcarcinoma
AT xuyi increaseinlongnoncodingrnapandarisassociatedwithpoorprognosisinclearcellrenalcellcarcinoma
AT tongyanyue increaseinlongnoncodingrnapandarisassociatedwithpoorprognosisinclearcellrenalcellcarcinoma
AT zhujianyong increaseinlongnoncodingrnapandarisassociatedwithpoorprognosisinclearcellrenalcellcarcinoma
AT leizhangming increaseinlongnoncodingrnapandarisassociatedwithpoorprognosisinclearcellrenalcellcarcinoma
AT wanlijun increaseinlongnoncodingrnapandarisassociatedwithpoorprognosisinclearcellrenalcellcarcinoma
AT zhuxiuwen increaseinlongnoncodingrnapandarisassociatedwithpoorprognosisinclearcellrenalcellcarcinoma
AT yefeng increaseinlongnoncodingrnapandarisassociatedwithpoorprognosisinclearcellrenalcellcarcinoma
AT xieliping increaseinlongnoncodingrnapandarisassociatedwithpoorprognosisinclearcellrenalcellcarcinoma